On January 24, 2023, Sarepta Therapeutics Inc. (NASDAQ: SRPT) opened at $128.95, higher 0.03% from the last session. During the day, the shares moved up to $133.47 and dropped to $127.83 before settling in for the closing price of $128.33. Price fluctuations for SRPT have ranged from $61.28 to $134.08 over the past 52 weeks.
Healthcare Sector giant saw their annual sales surged by 164.50% over the last five years. Company’s average yearly earnings per share was noted 27.50% at the time writing. With a float of $83.68 million, this company’s outstanding shares have now reached $87.63 million.
The firm has a total of 840 workers. Let’s measure their productivity. In terms of profitability, gross margin is +80.76, operating margin of -64.00, and the pretax margin is -59.69.
Sarepta Therapeutics Inc. (SRPT) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Sarepta Therapeutics Inc. is 0.20%, while institutional ownership is 89.10%. The most recent insider transaction that took place on Nov 17, was worth 94,311. In this transaction Director of this company sold 858 shares at a rate of $109.92, taking the stock ownership to the 6,387 shares. Before that another transaction happened on Sep 14, when Company’s Director bought 57,100 for $104.43, making the entire transaction worth $5,963,124. This insider now owns 108,178 shares in total.
Sarepta Therapeutics Inc. (SRPT) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 6/29/2022, the company posted -$2.65 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -$1.18) by -$1.47. This company achieved a net margin of -59.66 while generating a return on equity of -49.57. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.44 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 27.50% per share during the next fiscal year.
Sarepta Therapeutics Inc. (NASDAQ: SRPT) Trading Performance Indicators
Check out the current performance indicators for Sarepta Therapeutics Inc. (SRPT). In the past quarter, the stock posted a quick ratio of 4.00. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 12.62.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -8.21, a number that is poised to hit -1.35 in the next quarter and is forecasted to reach -4.91 in one year’s time.
Technical Analysis of Sarepta Therapeutics Inc. (SRPT)
Analysing the last 5-days average volume posted by the [Sarepta Therapeutics Inc., SRPT], we can find that recorded value of 0.9 million was lower than the volume posted last year of 1.08 million. As of the previous 9 days, the stock’s Stochastic %D was 76.60%. Additionally, its Average True Range was 4.47.
During the past 100 days, Sarepta Therapeutics Inc.’s (SRPT) raw stochastic average was set at 83.17%, which indicates a significant increase from 70.64% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 32.14% in the past 14 days, which was lower than the 34.76% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $121.35, while its 200-day Moving Average is $99.21. Now, the first resistance to watch is $131.95. This is followed by the second major resistance level at $135.53. The third major resistance level sits at $137.59. If the price goes on to break the first support level at $126.31, it is likely to go to the next support level at $124.25. Now, if the price goes above the second support level, the third support stands at $120.67.
Sarepta Therapeutics Inc. (NASDAQ: SRPT) Key Stats
There are currently 87,783K shares outstanding in the company with a market cap of 11.06 billion. Presently, the company’s annual sales total 701,890 K according to its annual income of -418,780 K. Last quarter, the company’s sales amounted to 230,270 K and its income totaled -257,740 K.